NOT APPLICABLE
NOT APPLICABLE
1. Field of the Invention
The present invention relates generally to medical systems and methods for treatment. More particularly, the present invention relates to apparatus and methods for treating aneurysms.
Aneurysms are enlargements or “bulges” in blood vessels which are often prone to rupture and which therefore present a serious risk to the patient. Aneurysms may occur in any blood vessel but are of particular concern when they occur in the cerebral vasculature or the patient's aorta.
The present invention is particularly concerned with aneurysms occurring in the aorta, particularly those referred to as aortic aneurysms. Abdominal aortic aneurysms (AAA's) are classified based on their location within the aorta as well as their shape and complexity. Aneurysms which are found below the renal arteries are referred to as infrarenal abdominal aortic aneurysms. Suprarenal abdominal aortic aneurysms occur above the renal arteries, while thoracic aortic aneurysms (TAA's) occur in the ascending, transverse, or descending part of the upper aorta.
Infrarenal aneurysms are the most common, representing about eighty percent (80%) of all aortic aneurysms. Suprarenal aneurysms are less common, representing about 20% of the aortic aneurysms. Thoracic aortic aneurysms are the least common and often the most difficult to treat.
The most common form of aneurysm is “fusiform,” where the enlargement extends about the entire aortic circumference. Less commonly, the aneurysms may be characterized by a bulge on one side of the blood vessel attached at a narrow neck. Thoracic aortic aneurysms are often dissecting aneurysms caused by hemorrhagic separation in the aortic wall, usually within the medial layer. The most common treatment for each of these types and forms of aneurysm is open surgical repair. Open surgical repair is quite successful in patients who are otherwise reasonably healthy and free from significant co-morbidities. Such open surgical procedures may be problematic, however, since access to the abdominal and thoracic aortas is difficult to obtain and because the aorta must be clamped off, placing significant strain on the patient's heart.
Over the past decade, endoluminal grafts have come into widespread use for the treatment of aortic aneurysm in patients who cannot undergo open surgical procedures. In general, endoluminal repairs access the aneurysm “endoluminally” through either or both iliac arteries in the groin. The grafts, which typically have been fabric or membrane tubes supported and attached by various stent structures, are then implanted, typically requiring several pieces or modules to be assembled in situ. Successful endoluminal procedures have a much shorter recovery period than open surgical procedures.
Present endoluminal aortic aneurysm repairs, however, suffer from a number of limitations. For example, a significant number of endoluminal repair patients experience leakage at the proximal juncture (attachment point closest to the heart) within two years of the initial repair procedure. While such leaks can often be fixed by further endoluminal procedures, the need to have such follow-up treatments significantly increases cost and is certainly undesirable for the patient. A less common but more serious problem has been graft migration. In instances where the graft migrates or slips from its intended position, open surgical repair is required. This is a particular problem since the patients receiving the endoluminal grafts are often those who are not considered to be good surgical candidates.
Further shortcomings of the present endoluminal graft systems relate to both deployment and configuration. For example, many of the commercially available endovascular systems are too large (above 12 F) for percutaneous introduction. Moreover, current devices often have an annular support frame that is stiff and difficult to deliver as well as unsuitable for treating many geometrically complex aneurysms, particularly infrarenal aneurysms with little space between the renal arteries and the upper end of the aneurysm, referred to as short-neck or no-neck aneurysms. Aneurysms having torturous geometries, are also difficult to treat.
In order to overcome some of the aforementioned challenges, the use of endograft systems having a scaffold structure and a filling structure has been proposed, such as in U.S. patent application Ser. No. 11/413,460 filed Apr. 28, 2006, the entire contents of which are incorporated herein by reference. These systems utilize a filling structure to help seal off and fill the aneurismal sac while creating a lumen for blood to traverse the aneurysm. Several references disclosing filling structures and which are the subject of the commonly owned, copending applications are described below. These systems may also include a stent-like scaffold which helps support the filling structure thereby further defining the lumen for blood flow. The filling structure may require a pre-filling step to help unfurl the filling structure prior to filling it with the hardenable filling material and an expandable balloon often is used to help support the endograft during filling and during hardening in order to ensure proper formation of a lumen for blood flow. Because the filling material may take some time to harden, the expanded balloon can occlude flow for an undesirable time. Additionally, even after filling and hardening of filling material in the filling structure, the aneurismal sac may not be completely sealed off and blood can still flow into the sac. For these reasons it would be desirable to provide alternative apparatus and methods that create a better seal between the aneurismal sac and the endograft. It would also be desirable to provide apparatus and methods that help filling structures expand and conform to the aneurysm anatomy. Moreover, it would also be desirable for sealing apparatus and methods to minimize or eliminate the need for a separate unfurling step as well as minimizing the need to use an inflated balloon for support during filling and hardening that can obstruct blood flow. It would also be desirable that the alternative apparatus have a low profile for ease of delivery and percutaneous introduction as well as flexibility to allow advancement of the device through torturous vessels such as the iliac arteries. It would further be desirable that such devices can accommodate a variety of different vessel and aneurysm anatomies. At least some of these objectives will be met by the inventions described hereinbelow.
2. Description of the Background Art
U.S. Patent Publication No. 2006/0025853 describes a double-walled filling structure for treating aortic and other aneurysms. Copending, commonly owned U.S. Patent Publication No. 2006/0212112, describes the use of liners and extenders to anchor and seal such double-walled filling structures within the aorta. The full disclosures of both these publications are incorporated herein by reference. PCT Publication No. WO 01/21108 describes expandable implants attached to a central graft for filling aortic aneurysms. See also U.S. Pat. Nos. 5,330,528; 5,534,024; 5,843,160; 6,168,592; 6,190,402; 6,312,462; 6,312,463; U.S. Patent Publications 2002/0045848; 2003/0014075; 2004/0204755; 2005/0004660; and PCT Publication No. WO 02/102282.
The present invention provides apparatus and methods for the treatment of aneurysms, particularly aortic aneurysms including both abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA).
In a first aspect of the present invention, a system for treating an aneurysm comprises at least a first double-walled filling structure having an outer wall and an inner wall and the filling structure is adapted to be filled with a hardenable fluid filling medium so that the outer wall conforms to the inside surface of the aneurysm and the inner surface forms a generally tubular lumen to provide blood flow. The first filling structure comprises a sealing feature which forms a fluid seal between the filling structure and the aneurysm or an adjacent endograft when the filling structure is filled with the hardenable fluid filling medium. This minimizes or prevents blood flow downstream of the seal.
The walls of the filling structure may comprise ePTFE and the seal may be disposed upstream of the aneurysm, for example in the aneurysm neck. Sometimes the walls of the filling structure may be coated with another polymer such as polyurethane. The tubular lumen may have a substantially circular cross-section and the first filling structure may comprise an elliptical cross-section when the filling structure is filled with the hardenable filling medium. The edges of the first filling structure may be sealed together so that the filling structure can withstand a filling pressure of up to 300 mm Hg above a patient's normal systolic blood pressure without bursting. Some systems may also comprise a thrombogenic material such as polyurethane, polycarbonate, polyester, ePTFE, polyolefin, parylene, gelatin and silicone. The thrombogenic material may be coupled with an outer surface of the first filling structure and it may be formed into one of sutures, felts, velours, weaves, knits, hydrogels, foams, coils, sheets and combinations thereof. The thrombogenic material may also comprise a thrombogenic drug.
In some embodiments the first filling structure may include a main body having a main body width and the sealing feature may comprise a narrow neck region that is coupled with the main body. The narrow neck region may have a width that is less than the main body width. The width of the narrow neck region may be approximately 2% to approximately 20% of the main body width. Sometimes the sealing feature may include a flat shoulder on an upper portion of the filling structure. Other embodiments may have a sealing feature which includes a tapered shoulder region on an upper portion of the filling structure.
Still, in other embodiments the first filling structure may comprise an upper layer of material having an upper layer width and a lower layer of material having a lower layer width that is wider than the upper layer width. The upper and lower layers are fixedly coupled together so as to form the sealing feature which comprises a substantially flat upper outer surface and an arcuate lower outer surface when the first filling structure is filled with hardenable filling medium. The first filling structure may comprise a D-shaped cross-section when filled with hardenable filling medium.
The sealing feature may comprise a tapered region in the tubular lumen with the taper disposed near an upper portion of the first filling structure. The tapered region may flare inwardly from the upper portion of the first filling structure to a lower portion of the first filling structure. In other embodiments, the first filling structure may comprise an upper layer of material and a lower layer of material, wherein at least a portion of the upper layer is fixedly coupled with at least a portion of the lower layer of material which forms the sealing feature. In this case, the sealing feature comprises an upper filling region and a lower filling region formed by the seal with the two filling regions in fluid communication with one another. The upper filling region may hold a smaller volume of filling medium than the lower filling region and the seal may be formed along a line. The line may extend from an outer edge of the first filling structure inward towards the tubular lumen.
In other embodiments, the system may further comprise a second double-walled filling structure having an outer wall and an inner wall, wherein the second filling structure is adapted to be filled with a hardenable fluid filling medium so that the outer wall conforms to the inside surface of the aneurysm and the inner surface forms a generally tubular lumen to provide blood flow. The second filling structure may comprise a sealing feature which forms a fluid seal between the filling structure and the aneurysm or an adjacent endograft when the second filling structure is filled with the hardenable fluid filling medium. This minimizes or prevents blood flow downstream of the seal. The sealing feature of the first double-walled filling structure may comprise an outer surface having a first shape and the sealing feature of the second double-walled filling structure may comprise an outer surface having a second shape. The first and second shapes may be complementary to one another. In some embodiments, the first and second shapes comprise complementary tapers.
In still other embodiments, the sealing feature may comprise a foam filled region of the first filling structure and the foam filled region may be discrete from the remainder of the first filling structure. The discrete foam filled region may be fluidly isolated from the region filled with the hardenable filling medium. In other embodiments, the sealing feature may comprise an arm in fluid communication with the region filled with the hardenable filling medium. Alternatively, the sealing feature may comprise a slot that is substantially transverse to a longitudinal axis of the first double-walled filling structure. The slot may at least partially bisect the first double-walled filling structure into two fillable sections. The foam may be substituted for any other material that provides the desired compliance to the foam filled region, such as gels, suture material, etc.
Some embodiments may have a sealing feature which comprises a winged region that flares radially outward from the first double-walled filling structure. The winged region may comprise a tapered shoulder on an outer surface of the first double-walled filling structure. The sealing feature may further comprise a tapered lower region in the tubular lumen which flares radially outward from an upper part to a lower part of the first filling structure. Sometimes the sealing feature may also comprise a restraining element that is disposed at least partially around the tubular lumen. The restraining element may be adapted to restrict radial expansion of the tubular lumen to a predetermined size or shape. Sometimes the restraining element comprises a band extending circumferentially around the tubular lumen.
The sealing feature may comprise an enlarged head region and a tapered lower region on the first filling structure. The tapered region flares radially outward as the distance from the head region increases. The sealing feature may comprise a lower tubular cuff region coupled with the first filling structure and a winged portion on the first filling structure. The sealing feature may also include an upper tubular cuff region coupled with the first filling structure. Sometimes the sealing feature includes a skeletal frame disposed in between the inner and outer walls of the first filling structure and the inner wall radially expands inward as the first filling structure is filled with hardenable filling material. Alternatively, the first filling structure may be disposed on the inside surface of a radially expandable scaffold and the sealing feature may comprise a portion of the inner wall that is adapted to radially expand inward to engage and seal against an adjacent endograft.
The sealing feature may comprise an angled bottom edge on the first filling structure. In some embodiments, the filling structure may comprise a straight top edge and the angled bottom edge forms an acute angle relative to the top edge. In other embodiments, the sealing feature comprises a discrete filling compartment separate from the filling space of the first double-walled filling structure and fluidly uncoupled thereto. The discrete filling compartment may have a rectangular shaped region and the hardenable filling medium may surround the discrete filling compartment. An elongate flexible filling tube may be slidably engaged with the discrete filling compartment and the filling space.
In other embodiments, the sealing feature may comprise a shoulder that is disposed on a lower portion of the first filling structure. The first filling structure may have a main body width and the shoulder may have a shoulder width that is less than the main body width. The sealing feature may comprise an undercut region in the first filling structure that is adapted to expand outwardly when the first filling structure is filled with hardenable filling material.
The sealing feature may include a plurality of filaments coupled with the first filling structure and extending axially therefrom. These filaments may include a thrombogenic material. The thrombogenic material may also be a cape that is disposed at least partially over the first filling structure and coupled thereto. The sealing feature could also be a thrombogenic annular ring that is disposed at least partially around the first filling structure. Other sealing features may include a plurality of flanges that are coupled with the first filling structure. The flanges may have a width that progressively decreases relative to an adjacent flange. Also, the flanges may have a thickness that progressively decreases relative to an adjacent flange.
In still other embodiments the sealing feature may comprise a skeletal frame that is coupled with the first filling structure. The skeletal frame may comprise a plurality of self-expanding struts that are adapted to radially expand outward along with the outer wall of the first filling structure. The skeletal frame may comprise a wire-like helically shaped filament made from a material such as nitinol.
The sealing feature may also comprise an upper and a lower tubular shaped cuff that is coupled with the first filling structure. At least one of the upper or lower cuffs may comprise a reinforced region. The reinforced region may comprise a wire-like frame and sometimes the upper and lower reinforced cuffs may be coupled together with a plurality of struts.
In still other embodiments, the sealing feature may comprise a pair of fillable legs that are coupled with the first filling structure. The sealing feature may comprise a first region of the first filling structure having a first compliance and a second region of the first filling structure having a second compliance different than the first compliance. One of these regions may be embossed and another region may remain unembossed.
The system may further comprise a delivery catheter that has an expandable tubular support such as a balloon, which can be positioned within the tubular lumen to carry the double-walled filling structure. The system may also comprise a scaffold that is radially expandable from a collapsed configuration to an expanded configuration. A filling port that is fluidly coupled with the filling structure may also be included in the system. The filling port may be an elastomeric plug, and may be adapted to receive the hardenable filling medium and also provides a seal to prevent leakage thereof. The filling port may be substantially contained within the inner lumen of the filling structure when the filling structure is filled with the hardenable filling medium.
In another embodiment of the invention, a system for treating an aneurysm comprises at least a first double-walled filling structure having an outer wall and an inner wall. The filling structure is adapted to be filled with a hardenable fluid filling medium so that the outer wall conforms to the inside surface of the aneurysm and the inner surface forms a generally tubular lumen to provide blood flow. The system also includes a filling port that is substantially contained within the generally tubular lumen of the filling structure when the filling structure is filled with the hardenable fluid filling medium. A first end of the generally tubular lumen may comprise an invaginated tapered portion that flares radially outward. A second end of the tubular lumen may comprise an invaginated tapered portion that flares radially outward. The second end may be opposite of the first end. The first filling structure may comprise a sealing feature that forms a fluid seal between the filling structure and the aneurysm or an adjacent endograft when the filling structure is filled with the hardenable fluid filling medium. This reduces or prevents blood flow downstream of the seal. The sealing feature may comprise a tapered shoulder region on at least one end of the filling structure. The outer wall of the filling structure may be invaginated into the filling structure thereby forming a convex exterior surface on one end of the filling structure when the filling structure is filled with the hardenable fluid filling medium. A convex exterior surface may also be similarly formed on a second end of the filling structure opposite the first end. Either convex exterior surface may taper radially inwardly to merge with the tubular lumen.
These and other embodiments are described in further detail in the following description related to the appended drawing figures.
Referring now to
In preferred embodiments, a system comprising two endografts may be used to treat an aneurysm, such as the system seen in
In treating an infrarenal abdominal aortic aneurysm using the pair of filling structures 112 and 212 illustrated in
After filling the filling structures 112 and 212 as illustrated in
As with the single filling structure embodiments, the double filling structure embodiments will include at least one separate scaffold deployed within each of the tubular blood flow lumens. The scaffolds will generally be stent-like or graft-like vascular structures and will be deployed within the tubular lumens using balloon or other expansion catheters (in the case of malleable or balloon-expandable scaffolds) or using constraining sheaths (in the case of self-expanding scaffolds).
Referring in particular to
Referring now to
Various modifications of the protocols described above will be within the scope of the present invention. For example, while the scaffolds have been shown as being delivered after deployment of the filling structure(s), it will also be possible to deliver the scaffolds simultaneously with or prior to deployment of the filling structures. Moreover, the scaffolds could be delivered on the same delivery catheter(s) used to deliver and/or shape the filling structures. The scaffolds could then be expanded at the same time as filling the filling structure or even prior to filling the filling structure. Additional details on these embodiments are disclosed in U.S. patent application Ser. No. 11/413,460, previously incorporated herein by reference.
The filling structure used in
The filling structure of
As previously discussed, these filling structures show promise in the treatment of aneurysms as they help seal the aneurysm and also they help fix an endograft system in place thereby minimizing the possibility of migration. However, the filling structures can still leak. Therefore, other filling structure configurations and features are disclosed herein which may provide better sealing.
In
Still another filling structure embodiment is seen in
In
While most of the filling structure embodiments disclosed above are described as being used when two endograft systems are deployed (e.g.
The previous embodiments generally are disposed over a scaffold structure and radially expand outward to seal against the aneurysm wall. In
The embodiments described above generally rely on radial expansion of a filling structure to form a seal. The use of thrombogenic materials in combination with a filling structure enhances the resulting seal. In
Still another embodiment of a filling structure is one that is seen in
Another filling structure embodiment is seen in
In addition to filling structures and thrombogenic materials, a resilient spring-like frame or skeleton may be used to help radially expand the filling structure into engagement with the aneurysm walls, thereby further enhancing the seal. For example, in
Reinforcing the ends of the filling structures may also provide a better seal since the reinforced region and/or lumen L will be rigid and cannot collapse.
A number of embodiments of filling structure have been disclosed. Any combination of these embodiments may also be made or substituted with one another. While use of the filling structures may have been described with respect to a two piece or a three piece endograft system, one of skill in the art will appreciate that any filling structure may be used in any endograft system. Additional features such as thrombogenic materials, thrombogenic agents, radially expanding frames and reinforced regions have also been discussed. Any of these features may also be used in combination with any of the filling structures.
A number of thrombogenic materials have also been disclosed such as polyurethanes, polycarbonates, polyesters, ePTFE, polyolefins, parylene, gelatin, silicone, etc. Any of these materials may be used as the thrombogenic material and these materials may be formed into any number of configurations such as sutures, felts, velours, weaves, knits, hydrogels, foams, embolization coils or sheets. Attachment methods include but are not limited to gluing, heat sealing, welding, sintering, suturing/sowing, electrospinning, spraying, vapor deposition or drape coating. The thrombogenic materials may be fabricated as a part of the filling structure or they may be introduced during deployment of the filling structure.
In addition to using thrombogenic materials, the surfaces of the filling structure may be modified in order to provide various material properties. For example, the surface may be textured, dimpled, etc. in order to provide a surface that helps provide the desired amount of thrombogenicity. Furthermore, the preferred embodiments have been disclosed as being composed of ePTFE with an inner layer of polyurethane. Other materials may be used as the filling structure base material and a second or third or even more layers of other materials may be coupled to the base layer in order to provide the desired material characteristics of the filling structure. Specific regions of the filling structure may also be modified with a material or drug to provide a desired effect, for example, a portion of the filling structure may be modified to be thrombogenic to help create a seal while other regions remain unmodified or modified to have a different effect. Other materials or therapeutic agents like heparin may also be applied to the surface of the tubular lumen to minimize thrombogenicity, or to promote healing and endothelialization as blood flows therethrough.
Filling materials may be any one or combination of materials that may fill the filling structure and be hardened in situ. Examples of filling materials include polyethylene glycol (PEG), silicones, etc. One of skill in the art will appreciate that any of the features disclosed herein may be substituted or combined with any of the embodiments described herein. Moreover, in this disclosure the filling structure is referred to as having an inner wall and an outer wall that may be filled and that can withstand pressures of approximately from about 30 mm Hg to about 300 mm Hg above normal systolic blood pressure. One will appreciate the filling structure may also have multiple layers. For example, as disclosed, often the filling structure comprises an ePTFE layer with a coating of polyurethane thereover. Additional layers with other materials may similarly be used in order to control the material properties such as porosity and compliance. Therapeutic agents may also be coupled to the filling structure such as a thrombogenic agent on the outside of the filling structure.
While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting in scope of the invention which is defined by the appended claims.
The present application is a non-provisional of, and claims the benefit of priority under 35 U.S.C. §119(e) of U.S. Provisional Application No. 61/058,810 filed Jun. 4, 2008, the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4565738 | Purdy | Jan 1986 | A |
4638803 | Rand | Jan 1987 | A |
4641653 | Rockey | Feb 1987 | A |
4704126 | Baswell | Nov 1987 | A |
4710192 | Liotta | Dec 1987 | A |
4728328 | Hughes et al. | Mar 1988 | A |
4731073 | Robinson | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4743258 | Ikada | May 1988 | A |
4763654 | Jang | Aug 1988 | A |
4856516 | Hillstead | Aug 1989 | A |
4858264 | Reinhart | Aug 1989 | A |
4892544 | Frisch | Jan 1990 | A |
4936057 | Rhoades | Jun 1990 | A |
4976692 | Atad | Dec 1990 | A |
5002532 | Gaiser | Mar 1991 | A |
5074845 | Miraki | Dec 1991 | A |
5104404 | Wolff | Apr 1992 | A |
5108417 | Sawyer | Apr 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5133732 | Wiktor | Jul 1992 | A |
5139480 | Hickle | Aug 1992 | A |
5156620 | Pigott | Oct 1992 | A |
5195984 | Schatz | Mar 1993 | A |
5199226 | Rose | Apr 1993 | A |
5217484 | Marks | Jun 1993 | A |
5222970 | Reeves | Jun 1993 | A |
5234437 | Sepetka | Aug 1993 | A |
5242399 | Lau | Sep 1993 | A |
5250071 | Palermo | Oct 1993 | A |
5261916 | Engelson | Nov 1993 | A |
5263964 | Purdy | Nov 1993 | A |
5292331 | Boneau | Mar 1994 | A |
5314444 | Gianturco | May 1994 | A |
5316023 | Palmaz et al. | May 1994 | A |
5330520 | Maddison et al. | Jul 1994 | A |
5330528 | Lazim | Jul 1994 | A |
5334217 | Das | Aug 1994 | A |
5350397 | Palermo | Sep 1994 | A |
5352199 | Tower | Oct 1994 | A |
5375612 | Cottenceau | Dec 1994 | A |
5383892 | Cardon | Jan 1995 | A |
5421955 | Lau | Jun 1995 | A |
5423849 | Engelson | Jun 1995 | A |
5425739 | Jessen | Jun 1995 | A |
5425744 | Fagan | Jun 1995 | A |
5441510 | Simpson | Aug 1995 | A |
5441515 | Khosravi | Aug 1995 | A |
5443477 | Marin | Aug 1995 | A |
5443496 | Schwartz | Aug 1995 | A |
5449373 | Pinchasik | Sep 1995 | A |
5485667 | Kleshinski | Jan 1996 | A |
5494029 | Lane | Feb 1996 | A |
5496277 | Termin | Mar 1996 | A |
5507767 | Maeda | Apr 1996 | A |
5507769 | Marin et al. | Apr 1996 | A |
5507771 | Gianturco | Apr 1996 | A |
5514115 | Frantzen | May 1996 | A |
5514154 | Lau | May 1996 | A |
5522882 | Gaterud | Jun 1996 | A |
5530528 | Houki et al. | Jun 1996 | A |
5531741 | Barbacci | Jul 1996 | A |
5534024 | Rogers et al. | Jul 1996 | A |
5545210 | Hess | Aug 1996 | A |
5549662 | Fordenbacher | Aug 1996 | A |
5549663 | Cottone, Jr. | Aug 1996 | A |
5554181 | Das | Sep 1996 | A |
5562641 | Flomenblit | Oct 1996 | A |
5562698 | Parker | Oct 1996 | A |
5562728 | Lazarus | Oct 1996 | A |
5569295 | Lam | Oct 1996 | A |
5578074 | Mirigian | Nov 1996 | A |
5578149 | De Scheerder | Nov 1996 | A |
5591195 | Taheri | Jan 1997 | A |
5591223 | Lock | Jan 1997 | A |
5591226 | Trerotola | Jan 1997 | A |
5591228 | Edoga | Jan 1997 | A |
5591230 | Horn | Jan 1997 | A |
5593417 | Rhodes | Jan 1997 | A |
5601600 | Ton | Feb 1997 | A |
5603721 | Lau | Feb 1997 | A |
5605530 | Fischell | Feb 1997 | A |
5607442 | Fischell | Mar 1997 | A |
5607445 | Summers | Mar 1997 | A |
5607468 | Rogers | Mar 1997 | A |
5609605 | Marshall | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5618299 | Khosravi | Apr 1997 | A |
5624411 | Tuch | Apr 1997 | A |
5630840 | Mayer | May 1997 | A |
5632760 | Sheiban | May 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632771 | Boatman | May 1997 | A |
D380266 | Boatman | Jun 1997 | S |
5634941 | Winston | Jun 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
D380831 | Kavteladze | Jul 1997 | S |
5662614 | Edoga | Sep 1997 | A |
5665117 | Rhodes | Sep 1997 | A |
5674241 | Bley | Oct 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683449 | Marcade | Nov 1997 | A |
5690643 | WiJay | Nov 1997 | A |
5693038 | Suzuki et al. | Dec 1997 | A |
5693067 | Purdy | Dec 1997 | A |
5693088 | Lazarus | Dec 1997 | A |
5697971 | Fischell | Dec 1997 | A |
5709707 | Lock | Jan 1998 | A |
5718713 | Frantzen | Feb 1998 | A |
5723004 | Dereume | Mar 1998 | A |
5725568 | Hastings | Mar 1998 | A |
5725572 | Lam | Mar 1998 | A |
5728068 | Leone | Mar 1998 | A |
5728131 | Frantzen | Mar 1998 | A |
5728158 | Lau | Mar 1998 | A |
5733303 | Israel et al. | Mar 1998 | A |
5735892 | Myers | Apr 1998 | A |
5735893 | Lau | Apr 1998 | A |
5741327 | Frantzen | Apr 1998 | A |
5741333 | Frid | Apr 1998 | A |
5746691 | Frantzen | May 1998 | A |
5755769 | Richard | May 1998 | A |
5755773 | Evans et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5766238 | Lau | Jun 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5776114 | Frantzen | Jul 1998 | A |
5776161 | Globerman | Jul 1998 | A |
5782907 | Frantzen | Jul 1998 | A |
5785679 | Abolfathi et al. | Jul 1998 | A |
5788626 | Thompson | Aug 1998 | A |
5797953 | Tekulve | Aug 1998 | A |
5800393 | Sahota | Sep 1998 | A |
5800512 | Lentz et al. | Sep 1998 | A |
5800514 | Nunez | Sep 1998 | A |
5800525 | Bachinski | Sep 1998 | A |
5807404 | Richter | Sep 1998 | A |
5810872 | Kanesaka | Sep 1998 | A |
5824036 | Lauterjung | Oct 1998 | A |
5824037 | Fogarty et al. | Oct 1998 | A |
5824040 | Cox | Oct 1998 | A |
5824049 | Ragheb | Oct 1998 | A |
5824054 | Khosravi et al. | Oct 1998 | A |
5824056 | Rosenberg | Oct 1998 | A |
5827321 | Roubin | Oct 1998 | A |
5836966 | St. Germain | Nov 1998 | A |
5843160 | Rhodes | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5846246 | Dirks | Dec 1998 | A |
5846261 | Kotula et al. | Dec 1998 | A |
5849037 | Frid | Dec 1998 | A |
5860998 | Robinson | Jan 1999 | A |
5863627 | Szycher | Jan 1999 | A |
5867762 | Rafferty et al. | Feb 1999 | A |
5868685 | Powell et al. | Feb 1999 | A |
5868708 | Hart | Feb 1999 | A |
5868782 | Frantzen | Feb 1999 | A |
5871537 | Holman et al. | Feb 1999 | A |
5873907 | Frantzen | Feb 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5879381 | Moriuchi | Mar 1999 | A |
5888660 | Landoni et al. | Mar 1999 | A |
5902332 | Schatz | May 1999 | A |
5919224 | Thompson | Jul 1999 | A |
5928279 | Shannon et al. | Jul 1999 | A |
5931866 | Frantzen | Aug 1999 | A |
5944750 | Tanner | Aug 1999 | A |
5947991 | Cowan | Sep 1999 | A |
5948184 | Frantzen | Sep 1999 | A |
5976178 | Goldsteen et al. | Nov 1999 | A |
5984955 | Wisselink | Nov 1999 | A |
5994750 | Yagi | Nov 1999 | A |
6007573 | Wallace | Dec 1999 | A |
6015431 | Thornton | Jan 2000 | A |
6022359 | Frantzen | Feb 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6056776 | Lau | May 2000 | A |
6066167 | Lau | May 2000 | A |
6066168 | Lau | May 2000 | A |
6083259 | Frantzen | Jul 2000 | A |
6093199 | Brown | Jul 2000 | A |
6099548 | Taheri | Aug 2000 | A |
6110198 | Fogarty et al. | Aug 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6123722 | Fogarty | Sep 2000 | A |
6124523 | Banas et al. | Sep 2000 | A |
6132457 | Chobotov | Oct 2000 | A |
6152144 | Lesh | Nov 2000 | A |
6152943 | Sawhney | Nov 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6187033 | Schmitt | Feb 2001 | B1 |
6187034 | Frantzen | Feb 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6190406 | Duerig et al. | Feb 2001 | B1 |
6193745 | Fogarty et al. | Feb 2001 | B1 |
6196230 | Hall et al. | Mar 2001 | B1 |
6203732 | Clubb | Mar 2001 | B1 |
6214022 | Taylor et al. | Apr 2001 | B1 |
6231562 | Khosravi et al. | May 2001 | B1 |
6235050 | Quiachon et al. | May 2001 | B1 |
6241761 | Villafana | Jun 2001 | B1 |
6254633 | Pinchuk et al. | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6280466 | Kugler | Aug 2001 | B1 |
6283991 | Cox et al. | Sep 2001 | B1 |
6290722 | Wang | Sep 2001 | B1 |
6290731 | Solovay et al. | Sep 2001 | B1 |
6293960 | Ken | Sep 2001 | B1 |
6296603 | Turnlund et al. | Oct 2001 | B1 |
6299597 | Buscemi et al. | Oct 2001 | B1 |
6299604 | Ragheb | Oct 2001 | B1 |
6312462 | McDermott et al. | Nov 2001 | B1 |
6312463 | Rourke et al. | Nov 2001 | B1 |
6325816 | Fulton, III | Dec 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6331184 | Abrams | Dec 2001 | B1 |
6331191 | Chobotov | Dec 2001 | B1 |
6334869 | Leonhardt et al. | Jan 2002 | B1 |
6344056 | Dehdashtian | Feb 2002 | B1 |
6375675 | Dehdashtian et al. | Apr 2002 | B2 |
6395019 | Chobotov | May 2002 | B2 |
6409757 | Trout, III et al. | Jun 2002 | B1 |
6432131 | Ravenscroft | Aug 2002 | B1 |
6451047 | McCrea | Sep 2002 | B2 |
6463317 | Kucharczyk et al. | Oct 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6527799 | Shanley | Mar 2003 | B2 |
6544276 | Azizi | Apr 2003 | B1 |
6547804 | Porter et al. | Apr 2003 | B2 |
6554858 | Dereume et al. | Apr 2003 | B2 |
6576007 | Dehdashtian et al. | Jun 2003 | B2 |
6579301 | Bales | Jun 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6613037 | Khosravi et al. | Sep 2003 | B2 |
6645242 | Quinn | Nov 2003 | B1 |
6656214 | Fogarty et al. | Dec 2003 | B1 |
6656220 | Gomez et al. | Dec 2003 | B1 |
6663607 | Slaikeu et al. | Dec 2003 | B2 |
6663667 | Dehdashtian et al. | Dec 2003 | B2 |
6679300 | Sommer et al. | Jan 2004 | B1 |
6682546 | Amplatz | Jan 2004 | B2 |
6692486 | Jaafar et al. | Feb 2004 | B2 |
6695833 | Frantzen | Feb 2004 | B1 |
6729356 | Baker et al. | May 2004 | B1 |
6730119 | Smalling | May 2004 | B1 |
6733521 | Chobotov | May 2004 | B2 |
6761733 | Chobotov | Jul 2004 | B2 |
6773454 | Wholey et al. | Aug 2004 | B2 |
6776771 | Van Moorlegem et al. | Aug 2004 | B2 |
6827735 | Greenberg | Dec 2004 | B2 |
6843803 | Ryan et al. | Jan 2005 | B2 |
6878161 | Lenker | Apr 2005 | B2 |
6878164 | Kujawski | Apr 2005 | B2 |
6887268 | Butaric et al. | May 2005 | B2 |
6918926 | Letort | Jul 2005 | B2 |
6945989 | Betelia et al. | Sep 2005 | B1 |
6958051 | Hart et al. | Oct 2005 | B2 |
6960227 | Jones et al. | Nov 2005 | B2 |
7022100 | Aboul-Hosn et al. | Apr 2006 | B1 |
7105012 | Trout, III | Sep 2006 | B2 |
7112217 | Kugler | Sep 2006 | B1 |
7122052 | Greenhalgh | Oct 2006 | B2 |
7131991 | Zarins et al. | Nov 2006 | B2 |
7147661 | Chobotov et al. | Dec 2006 | B2 |
7175651 | Kerr | Feb 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7314483 | Landau et al. | Jan 2008 | B2 |
7326237 | Depalma et al. | Feb 2008 | B2 |
7435253 | Hartley et al. | Oct 2008 | B1 |
7530988 | Evans et al. | May 2009 | B2 |
7666220 | Evans et al. | Feb 2010 | B2 |
7682383 | Robin | Mar 2010 | B2 |
7708773 | Pinchuk et al. | May 2010 | B2 |
7790273 | Lee et al. | Sep 2010 | B2 |
7828838 | Bolduc et al. | Nov 2010 | B2 |
7951448 | Lee et al. | May 2011 | B2 |
20010020184 | Dehdashtian et al. | Sep 2001 | A1 |
20010027337 | Di Caprio | Oct 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010044655 | Patnaik et al. | Nov 2001 | A1 |
20020019665 | Dehdashtian et al. | Feb 2002 | A1 |
20020026217 | Baker et al. | Feb 2002 | A1 |
20020045848 | Jaafar et al. | Apr 2002 | A1 |
20020045931 | Sogard et al. | Apr 2002 | A1 |
20020052643 | Wholey et al. | May 2002 | A1 |
20020077594 | Chien et al. | Jun 2002 | A1 |
20020151953 | Chobotov | Oct 2002 | A1 |
20020151956 | Chobotov | Oct 2002 | A1 |
20020151958 | Chuter | Oct 2002 | A1 |
20020156518 | Tehrani | Oct 2002 | A1 |
20020165521 | Cioanta et al. | Nov 2002 | A1 |
20020169497 | Wholey et al. | Nov 2002 | A1 |
20020183629 | Fitz | Dec 2002 | A1 |
20030004560 | Chobotov | Jan 2003 | A1 |
20030009132 | Schwartz et al. | Jan 2003 | A1 |
20030014075 | Rosenbluth et al. | Jan 2003 | A1 |
20030028209 | Teoh et al. | Feb 2003 | A1 |
20030036745 | Khosravi et al. | Feb 2003 | A1 |
20030051735 | Pavcnik et al. | Mar 2003 | A1 |
20030074056 | Killion et al. | Apr 2003 | A1 |
20030078647 | Vallana et al. | Apr 2003 | A1 |
20030093145 | Lawrence-Brown et al. | May 2003 | A1 |
20030130720 | DePalma et al. | Jul 2003 | A1 |
20030130725 | DePalma et al. | Jul 2003 | A1 |
20030135269 | Swanstrom | Jul 2003 | A1 |
20030204242 | Zarins et al. | Oct 2003 | A1 |
20030204249 | Letort | Oct 2003 | A1 |
20030216802 | Chobotov | Nov 2003 | A1 |
20030220649 | Bao et al. | Nov 2003 | A1 |
20030225446 | Hartley | Dec 2003 | A1 |
20040016997 | Ushio | Jan 2004 | A1 |
20040044358 | Khosravi et al. | Mar 2004 | A1 |
20040082989 | Cook et al. | Apr 2004 | A1 |
20040091543 | Bell et al. | May 2004 | A1 |
20040098096 | Eton | May 2004 | A1 |
20040116997 | Taylor et al. | Jun 2004 | A1 |
20040147811 | Diederich et al. | Jul 2004 | A1 |
20040153025 | Seifert et al. | Aug 2004 | A1 |
20040167607 | Frantzen | Aug 2004 | A1 |
20040193245 | Deem et al. | Sep 2004 | A1 |
20040204755 | Robin | Oct 2004 | A1 |
20040215172 | Chu et al. | Oct 2004 | A1 |
20040215316 | Smalling | Oct 2004 | A1 |
20040220522 | Briscoe et al. | Nov 2004 | A1 |
20040243057 | Vinten-Johansen et al. | Dec 2004 | A1 |
20050004660 | Rosenbluth et al. | Jan 2005 | A1 |
20050027238 | Fago et al. | Feb 2005 | A1 |
20050028484 | Littlewood | Feb 2005 | A1 |
20050065592 | Holzer | Mar 2005 | A1 |
20050090804 | Chobotov et al. | Apr 2005 | A1 |
20050096731 | Looi et al. | May 2005 | A1 |
20050215989 | Abboud et al. | Sep 2005 | A1 |
20050245891 | McCormick et al. | Nov 2005 | A1 |
20050251251 | Cribier | Nov 2005 | A1 |
20060015173 | Clifford et al. | Jan 2006 | A1 |
20060025853 | Evans et al. | Feb 2006 | A1 |
20060074481 | Vardi et al. | Apr 2006 | A1 |
20060135942 | Fernandes et al. | Jun 2006 | A1 |
20060142836 | Hartley et al. | Jun 2006 | A1 |
20060155369 | Edwin et al. | Jul 2006 | A1 |
20060161244 | Seguin | Jul 2006 | A1 |
20060184109 | Gobel | Aug 2006 | A1 |
20060206197 | Morsi | Sep 2006 | A1 |
20060212112 | Evans et al. | Sep 2006 | A1 |
20060265043 | Mandrusov et al. | Nov 2006 | A1 |
20060292206 | Kim et al. | Dec 2006 | A1 |
20070032850 | Ruiz et al. | Feb 2007 | A1 |
20070043420 | Lostetter | Feb 2007 | A1 |
20070050008 | Kim et al. | Mar 2007 | A1 |
20070055355 | Kim et al. | Mar 2007 | A1 |
20070061005 | Kim et al. | Mar 2007 | A1 |
20070150041 | Evans et al. | Jun 2007 | A1 |
20070162106 | Evans et al. | Jul 2007 | A1 |
20070162109 | Davila et al. | Jul 2007 | A1 |
20070208416 | Burpee et al. | Sep 2007 | A1 |
20070276477 | Lee et al. | Nov 2007 | A1 |
20080039923 | Taylor et al. | Feb 2008 | A1 |
20080154368 | Justis et al. | Jun 2008 | A1 |
20080228259 | Chu | Sep 2008 | A1 |
20080294237 | Chu | Nov 2008 | A1 |
20090099649 | Chobotov et al. | Apr 2009 | A1 |
20090198267 | Evans et al. | Aug 2009 | A1 |
20090209855 | Drilling et al. | Aug 2009 | A1 |
20090216125 | Lenker | Aug 2009 | A1 |
20090318949 | Ganpath et al. | Dec 2009 | A1 |
20090319029 | Evans et al. | Dec 2009 | A1 |
20100004728 | Rao et al. | Jan 2010 | A1 |
20100036360 | Herbowy et al. | Feb 2010 | A1 |
20100106087 | Evans et al. | Apr 2010 | A1 |
20100217383 | Leonhardt et al. | Aug 2010 | A1 |
20120016456 | Herbowy et al. | Jan 2012 | A1 |
Number | Date | Country |
---|---|---|
4010975 | Oct 1991 | DE |
95302708.3 | Nov 1995 | EP |
1325717 | Jul 2003 | EP |
1903985 | Apr 2008 | EP |
2834199 | Apr 2003 | FR |
4-322665 | Nov 1992 | JP |
2003-525692 | Sep 2003 | JP |
2004-537353 | Dec 2004 | JP |
2005-505380 | Feb 2005 | JP |
2005-532120 | Oct 2005 | JP |
2008-510502 | Apr 2008 | JP |
9717912 | May 1997 | WO |
9719653 | Jun 1997 | WO |
9853761 | Dec 1998 | WO |
9900073 | Jan 1999 | WO |
9944539 | Sep 1999 | WO |
0029060 | May 2000 | WO |
0051522 | Sep 2000 | WO |
WO 0121108 | Mar 2001 | WO |
0166038 | Sep 2001 | WO |
02078569 | Oct 2002 | WO |
02083038 | Oct 2002 | WO |
WO 02102282 | Dec 2002 | WO |
03007785 | Jan 2003 | WO |
03032869 | Apr 2003 | WO |
03037222 | May 2003 | WO |
03053288 | Jul 2003 | WO |
2004004603 | Jan 2004 | WO |
2004026183 | Apr 2004 | WO |
2004026183 | Apr 2004 | WO |
2004037116 | May 2004 | WO |
2004037116 | May 2004 | WO |
2004045393 | Jun 2004 | WO |
2006012567 | Feb 2006 | WO |
2006116725 | Nov 2006 | WO |
2007008600 | Jan 2007 | WO |
2007142916 | Dec 2007 | WO |
Entry |
---|
Gilling-Smith, “Stent Graft Migration After Endovascular Aneurysm Repair,” presented at 25th International Charing Cross Symposium, Apr. 13, 2003 [Power Point Presentation and Transcript], 56 pages total. |
Carmi et al., “Endovascular stent-graft adapted to the endoluminal environment: prototype of a new endoluminal approach,” J Endovasc Ther. Jun. 2002;9(3):380-381. |
International Search Report and Written Opinion of PCT Application No. PCT/US2009/046310, dated Jul. 29, 2009, 9 pages total. |
U.S. Appl. No. 61/052,059, filed May 9, 2008; first named inventor: Gwendolyn A. Watanabe. |
Examination Report of corresponding Japanese Application No. 2011-512667, dated Jun. 18, 2013. |
Patrick W. Serruys and Michael JB Kutryk; Handbook of Coronary Stents, Second Edition; 1998; pp. 45, 55, 78, 103, 112, 132, 158, 174, 185, 190, 207, 215, 230, 239; Martin Dunitz; UK. |
Journal of Endovascular Therapy; Apr. 2000; pp. 111, 114, 132-140; vol. 7′ No. 2; International Society of Endovascular Specialists; Phoenix, AZ. |
Donayre et al., “Fillable Endovascular Aneurysm Repair,” Endovascular Today, pp. 64-66, Jan. 2009. |
International Search Report of PCT/US 06/16403, dated Aug. 7, 2007. 2 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US2006/062257, mailed Jan. 18, 2008. 7 pages total. |
International Search Report and Written Opinion of PCT Application No. PCT/US07/69671, dated Jul. 7, 2008, 9 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US09/34136, D dated Apr. 8, 2009, 16 pages total. |
U.S. Appl. No. 12/371,087, filed Feb. 13, 2009, first named inventor: K.T. Venkateswara Rao. |
International Search Report and Written Opinion of PCT Application No. PCT/US09/41718, dated Jun. 22, 2009, 23 pages total. |
Supplementary European Search Report and Search Opinion of EP Patent Application No. 05773726, mailed Apr. 23, 2010, 6 pages total. |
International Search Report and The Written Opinion of the International Searching Authority, Issued in PCT/US2012/032612 on Jul. 25, 2012, 13 pages. |
The International Search Report of the International Searching Authority for Application No. PCT/US2012/021878, mailed on May 23, 2012, 4 pages. |
The Written Opinion, including the search, of the International Searching Authority for Application No. PCT/US2012/021878, mailed May 23, 2012, 9 pages. |
Extended European search report of corresponding EP Application No. 06751879.5, dated Apr. 16, 2013. 9 pages. |
European Search Report and Search Opinion of EP Patent Application No. 06774540.6, mailed Mar. 30, 2010, 6 pages total. |
EP report, dated Nov. 7, 2013, of corresponding EP Application No. 09733719.0. |
Search report dated Oct. 17, 2013 of corresponding PCT/US2012/032612. |
International Preliminary Report on Patentability PCT/US2012/021878 dated Aug. 1, 2013. |
Report of European Patent Application No. 06850439.8 dated May 15, 2013. |
Report for European Patent Application No. 06850439.8, dated Aug. 8, 2012. |
Examination report for JP Application. No. 2008-547709 dated Dec. 13, 2011. |
International Search Report and Written Opinion of PCT Application No. PCT /US2009/046308, mailed Nov. 17, 2009, 12 pages total. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, Issued in PCT/US2010/061621 on Jul. 12,2012, 7 pages. |
PCT International Search Report and Written Opinion dated Feb. 28, 2011 for PCT Application No. PCT/US2010/61621. 11 pages. |
U.S. Appl. No. 60/855,889, filed Oct. 31, 2006; first named inventor: Steven L. Herbowy. |
U.S. Appl. No. 12/429,474, filed Apr. 24, 2009; first named inventor: Steven L. Herbowy. |
William Tanski, Mark Fillinger. Outcomes of original and low-permeability Gore Excluder endoprosthesis for endovascular abdominal aortic aneurysm repair. Journal of Vascular Surgery. Feb. 2007. p. 243-249. |
Susan M. Trocciola et al. The development of endotension is associated with increased transmission of pressure and serous components in porous expanded polytetrafluoroethylene stent-grafts: Characterization using a canine model. Journal of Vascular Surgery. Jan. 2006. p. 109-116. |
Shan-e-ali Haider et al. Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: 12-month comparison to the original Excluder device. Journal of Vascular Surgery. vol. 44, No. 4. 694-700. Oct. 2006. |
Examination report of EP Application No. 06751879.5, dated Mar. 24, 2014. 5 pages. |
Examination Report of Japanese Patent Application No. 2007-522822, dated Feb. 8, 2011. |
Examination Report of Japanese Patent Application No. 2011-506487, dated Jun. 11, 2013. |
Official Action for Japanese Patent Application No. 2008-547709; dated Oct. 30, 2012. |
Examination Report of Japanese Patent Application No. 2008-547709, dated Jul. 22, 2013. |
Examination Report of European Patent Application 03754880.7; dated Dec. 16, 2010. |
Examination Report of European Patent Application 03754880.7; dated Dec. 22, 2011. |
Examination Report of European App. 03754880.7, dated Feb. 22, 2013. |
Examination Report of European Application No. 03754880.7; dated Jun. 29, 2012. 4 pages. |
Extended European Search Report of Application No. 11180827.5, dated Jan. 30, 2012. 6 pages. |
Search report of corresponding PCT/US2014/021928, mailed May 20, 2014. 8 pages. |
Examination Report of Japanese Patent Application No. 2011-506487, dated May 7, 2014. |
Number | Date | Country | |
---|---|---|---|
20090318949 A1 | Dec 2009 | US |
Number | Date | Country | |
---|---|---|---|
61058810 | Jun 2008 | US |